Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Tumor Immunotherapy01:27

Tumor Immunotherapy

556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self‑Reported Oral Health and Malnutrition Risk in Community-Dwelling Older U.S. Adults.

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·2026
Same author

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same author

Oral Frailty as a Marker of Intrinsic Capacity Decline: A Narrative Review on a Multisystemic Ageing Perspective.

Journal of oral rehabilitation·2026
Same author

Periodontal Disease as a Marker of Malnutrition Risk in Community-Dwelling Older Adults.

Journal of the American Medical Directors Association·2026
Same author

Biopsychosocial frailty and the incident risk of cardio- and cerebrovascular diseases: an 8-year follow-up of the italian longitudinal study on aging.

GeroScience·2026
Same author

Tooth Loss as a Risk Factor of Declining Intrinsic Capacity Domains in Later Life: Evidence From NHANES 2009-2014.

Journal of oral rehabilitation·2025

Related Experiment Video

Updated: Jul 18, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

Passive tau-based immunotherapy for tauopathies.

Francesco Panza1, Vincenzo Solfrizzi2, Antonio Daniele3

  • 1Unit of Research Methodology and Data Sciences for Population Health, National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari, Italy.

Handbook of Clinical Neurology
|August 24, 2023
PubMed
Summary
This summary is machine-generated.

Developing disease-modifying drugs for tauopathies, including Alzheimer's disease (AD), remains challenging. Current research focuses on tau-targeted passive immunotherapies, with several anti-tau antibodies in clinical trials for primary and secondary tauopathies.

Keywords:
Alzheimer's diseaseFTLD-TauMild cognitive impairmentMonoclonal antibodiesPSPSTau

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

6.0K

Related Experiment Videos

Last Updated: Jul 18, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

6.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Tauopathies are complex neurological disorders characterized by abnormal tau protein aggregation.
  • Limited progress has been made in developing effective disease-modifying treatments for primary and secondary tauopathies, including Alzheimer's disease (AD).
  • Existing symptomatic treatments for tauopathies offer limited efficacy.

Approach:

  • Investigating tau-targeted passive immunotherapy as a therapeutic strategy.
  • Developing anti-tau antibodies to interfere with tau aggregation or promote its clearance.
  • Clinical trials are evaluating multiple anti-tau monoclonal antibodies for treating various tauopathies.

Key Points:

  • Twelve anti-tau antibodies have entered clinical trials, with seven currently in testing for primary tauopathies and AD.
  • Semorinemab is the most advanced anti-tau antibody for AD, while bepranemab is in trials for progressive supranuclear palsy syndrome.
  • Several anti-tau antibodies have been discontinued, highlighting the challenges in this therapeutic area.

Conclusions:

  • Passive immunotherapy represents a promising avenue for treating tauopathies.
  • Ongoing Phase I/II trials will provide further evidence on the efficacy of these novel immunotherapeutics.
  • Further research and clinical development are crucial for advancing tauopathy treatments.